Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to $1.6 million.

  • Bioadaptives' Total Current Liabilities fell 1415.87% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 1415.87%. This contributed to the annual value of $1.7 million for FY2024, which is 141.81% down from last year.
  • Latest data reveals that Bioadaptives reported Total Current Liabilities of $1.6 million as of Q3 2025, which was down 1415.87% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Bioadaptives' Total Current Liabilities ranged from a high of $1.9 million in Q2 2024 and a low of $1.2 million during Q1 2021
  • Over the past 5 years, Bioadaptives' median Total Current Liabilities value was $1.6 million (recorded in 2025), while the average stood at $1.6 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 2753.16% in 2022, then plummeted by 2707.32% in 2025.
  • Quarter analysis of 5 years shows Bioadaptives' Total Current Liabilities stood at $1.2 million in 2021, then grew by 19.91% to $1.5 million in 2022, then grew by 17.59% to $1.8 million in 2023, then decreased by 1.42% to $1.7 million in 2024, then dropped by 7.89% to $1.6 million in 2025.
  • Its Total Current Liabilities stands at $1.6 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.7 million for Q1 2025.